EUCTR2007-000343-10-DE进行中（未招募）不适用
A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects =60 Years of Age
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 12,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 60 years.
- •2. Signed an informed consent prior to any study procedure.
- •3. Afebrile (<101.0°F [<38.3°C] oral or equivalent) on day of vaccination.
- •4. Females must be postmenopausal or have a negative serum or urine pregnancy test.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. A history of allergic reaction to any vaccine component (including gelatin), or an anaphylactic/anaphylactoid reaction to neomycin (note that subjects/patients with a history of contact dermatitis from neomycin may receive the vaccine).
- •2. Prior receipt of any varicella or zoster vaccine.
- •3. Any live virus vaccine administered within 4 weeks prevaccination or scheduled during the 42-day postvaccination period.
- •4. Any inactivated vaccine, except for influenza vaccine, administered within 7 days prevaccination or scheduled during the 42-day postvaccination period.
- •5. Subject is pregnant or breastfeeding.
- •6. Participation in an investigational drug or vaccine study within the last 30 days prior to enrollment or expected during the 42-day postvaccination period.
- •7. An intercurrent illness (including active untreated tuberculosis) that might interfere with the interpretation of the study or prevent the subject from completion of the study.
- •8. Use of immunosuppressive therapy. Subjects on corticosteroids should be excluded if they are receiving or are expected to receive, in the period from 4 weeks prior to enrollment until 4 weeks postvaccination, systemic doses greater than required for physiological replacement, i.e., >5 mg of prednisone (or equivalent) and for >2 weeks. Excluded immunosuppressive therapies also include chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation.
- •9. Known or suspected immune dysfunction that is caused by a medical condition or any other cause. Examples of medical conditions associated with immune dysfunction include congenital immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, or generalized malignancy. Subjects with a history of cancer who are not on active treatment and are not thought to be immunosuppressed at enrollment will be eligible for enrollment.
- •10. Note: Subjects with prostate or breast cancer who are not on chemotherapeutic drugs (other than hormone blocking drugs), subjects with skin cancer who are not receiving radiation therapy or chemotherapy, and subjects with a history of other malignancies who have been disease-free for at least 6 months, will be eligible for enrollment.
- •11. Any concomitant use of nontopical antiviral therapy with activity against herpesviruses, including but not limited to acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, brivudine, and cidofovir.
- •12. Any other reason that in the opinion of the investigator might interfere with the evaluation required by the study.
研究者
相似试验
进行中（未招募）
4 期
Eye drops in Indian Subjects to treat dry eyeCTRI/2022/03/041175Alcon Research Ltd177
进行中（未招募）
1 期
A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects =60 Years of AgeMedDRA version: 9.1 Level: LLT Classification code 10019974 Term: Herpes zosterHerpes ZosterEUCTR2007-000343-10-GBMerck & Co. Inc.12,000
撤回
4 期
A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX in Subjects >=60 Years of Ageshingles10047438Herpes ZosterNL-OMON31293Merck750
进行中（未招募）
4 期
A study to evaluate safety and effectiveness of Apremilast drug in patients suffering from a disease of stiff and swollen joints (arthritis) along with disease of skin (psoriasis)CTRI/2019/01/017122Glenmark Pharmaceuticals Ltd
已完成
不适用
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted with MPLA Liposomes, in Healthy, HIV-Uninfected AdultsNL-OMON48531Academisch Medisch Centrum24